First-in-class non-opioid analgesics: Molecular mechanisms and clinical impact of suzetrigine

Effective and safe pain management remains a challenge for clinicians and researchers, despite the fact that pain is one of the most common and important clinical challenges in medicine. Despite their well-established risks of addiction, tolerance, respiratory depression, and a host of other negative effects, opioid analgesics continued to be the standard treatment for moderate to severe pain for many years. Recent scientific discoveries and regulatory initiatives have encouraged the creation of non-opioid analgesics with unique modes of action. As the first in a new class of non-opioid, peripherally acting painkillers approved by the U.S. Food and Drug Administration in 2025, suzetrigine, marketed as Journavx™-represents a significant milestone. This article synthesizes current knowledge on the pharmacology, molecular mechanism, clinical efficacy, safety, and potential impact of suzetrigine in pain management.